Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Holding INCY?
Track your performance easily
INCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.27 - $70.36
Previous Close$66.43
Volume742.38K
Average Volume (3M)1.92M
Market Cap
$12.79B
Enterprise Value$11.31B
Total Cash (Recent Filing)$1.52B
Total Debt (Recent Filing)$32.62M
Price to Earnings (P/E)187.2
Beta0.74
Next Earnings
Oct 29, 2024EPS Estimate
$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding192,598,027
10 Day Avg. Volume1,162,793
30 Day Avg. Volume1,924,664
Standard Deviation0.08
R-Squared0.20
Alpha-0.00767
Financial Highlights & Ratios
Price to Book (P/B)4.27
Price to Sales (P/S)3.30
Price to Cash Flow (P/CF)-5.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.93
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda25.75
Forecast
1Y Price Target
$73.56Price Target Upside10.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIncyte presented early data for its potential first-in-class CDK2 inhibitor, which demonstrated encouraging signs of clinical activity in patients with solid tumors, most notably those with ovarian cancer.
Product DevelopmentManagement has a three-pronged focus on continued dominance in hematology, developing major products in solid oncology, and making a major push into inflammation and immunology.
Strategic PositioningIncyte has strategically positioned INCB123667 in ovarian and endometrial cancer, given the promising efficacy as well as safety/tolerability in early development.
Bears Say
Financial PerformanceNet income of $(445 million) and EPS of $(2.04) were below consensus estimates of $145 million and $0.65.
Pipeline And Clinical TrialsCurrent combo trials with ruxolitinib are planned to start, but completion is planned too close to Jakafi's loss of exclusivity to buoy sentiment or concerns on revenue cliff.
Revenue ChallengesIncyte is facing a major revenue cliff due to generics entering the market to threaten Jakafi revenue.
---
Ownership Overview
15.66% Insiders
24.05% Mutual Funds
0.78% Other Institutional Investors
34.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $50.27 and its highest was $70.36 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Oct 29, 2024 which is in 10 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 30, 2024. The company reported -$1.818 earnings per share for the quarter, missing the consensus estimate of $0.748 by -$2.566.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is $1.14.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 192,598,020 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of -$1.818 in its last earnings report, missing expectations of $0.748. Following the earnings report the stock price went down -1.166%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.56 (10.80% Upside)
$73.56 (10.80% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 6.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.15%
12-Months-Change
Fundamentals
Return on Equity
2.51%
Trailing 12-Months
Asset Growth
-24.91%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q2 2024
0:00 / 0:00
---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$73.56
▲(10.80% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
16/20 ratings generated profit
1 Year Average Return
+8.43%
reiterated a buy rating 3 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +8.43% per trade.
---